Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2011

01-02-2011 | Commentary

Treatment of candidemia in adult patients without neutropenia - an inconvenient truth

Authors: Pedro Póvoa, João Gonçalves-Pereira

Published in: Critical Care | Issue 1/2011

Login to get access

Abstract

In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.
Literature
1.
Pappas PG, Kauff man CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48: 503-535. 10.1086/596757PubMedCrossRef
2.
Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38: 161-189. 10.1086/380796PubMedCrossRef
3.
Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M: Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008, 83: 1011-1021. 10.4065/83.9.1011PubMedCrossRef
4.
Mills EJ, Perri D, Cooper C, Nachega JB, Wu P, Tleyjeh I, Phillips P: Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob 2009, 8: 23. 10.1186/1476-0711-8-23PubMedPubMedCentralCrossRef
5.
Bennett JE: Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006, 355: 1154-1159. 10.1056/NEJMct060052PubMedCrossRef
6.
Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356: 2472-2482. 10.1056/NEJMoa066906PubMedCrossRef
7.
Gotzsche PC: Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006, 295: 1172-1174. 10.1001/jama.295.10.1172PubMedCrossRef
8.
Kaul S, Diamond GA: Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog Cardiovasc Dis 2007, 49: 284-299. 10.1016/j.pcad.2006.10.001PubMedCrossRef
9.
Sobel JD, Revankar SG: Echinocandins - first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007, 356: 2525-2526. 10.1056/NEJMe078078PubMedCrossRef
10.
11.
Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32: 686-693. 10.1086/319211PubMedCrossRef
12.
Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29: 1402-1407. 10.1086/313498PubMedCrossRef
13.
Johansen HK, Gøtzsche PC: Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000, CD000969.
14.
Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R: In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004, 48: 4453-4456. 10.1128/AAC.48.11.4453-4456.2004PubMedPubMedCentralCrossRef
15.
Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A: Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004, 48: 2477-2482. 10.1128/AAC.48.7.2477-2482.2004PubMedPubMedCentralCrossRef
Metadata
Title
Treatment of candidemia in adult patients without neutropenia - an inconvenient truth
Authors
Pedro Póvoa
João Gonçalves-Pereira
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9414

Other articles of this Issue 1/2011

Critical Care 1/2011 Go to the issue

Commentary

Immunity, inflammation and sepsis: new insights and persistent questions

Research

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis

Research

A new technique for bedside placement of enteral feeding tubes: a prospective cohort study

Research

Plasma acetate, gluconate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte 148 with a bicarbonate-balanced solution

Research

Risk assessment in the first fifteen minutes: a prospective cohort study of a simple physiological scoring system in the emergency department

Research

Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study